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ARTICLE
Translational Therapeutics
Systemic immune response induced by oxaliplatin-based
neoadjuvant therapy favours survival without metastatic
progression in high-risk rectal cancer
Erta Kalanxhi1, Sebastian Meltzer1,2, Jakob Vasehus Schou3, Finn Ole Larsen3, Svein Dueland4, Kjersti Flatmark2,5,6,
Benny Vittrup Jensen3, Knut Håkon Hole7, Therese Seierstad7, Kathrine Røe Redalen1,8, Dorte Lisbet Nielsen3 and Anne Hansen Ree1,2
BACKGROUND: Systemic failure remains a challenge in rectal cancer. We investigated the possible systemic anti-tumour immune
activity invoked within oxaliplatin-based neoadjuvant therapy.
METHODS: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 ligand (Flt3L), a
factor reﬂecting both therapy-induced myelosuppression and activation of tumour antigen-presenting dendritic cells, at baseline
and following induction chemotherapy and sequential chemoradiotherapy, both modalities containing oxaliplatin. The primary end
point was progression-free survival (PFS).
RESULTS: In both cohorts, the median Flt3L level was signiﬁcantly higher at completion of each sequential modality than at
baseline. The 5-year PFS (most events being metastatic progression) was 68% and 71% in the two cohorts consisting of 33% and
52% T4 cases. In the principal cohort, a high Flt3L level following the induction chemotherapy was associated with low risk for a PFS
event (HR: 0.15; P < 0.01). These patients also had available dose scheduling and toxicity data, revealing that oxaliplatin dose
reduction during chemoradiotherapy, undertaken to maintain compliance to the radiotherapy protocol, was associated with
advantageous PFS (HR: 0.47; P= 0.046).
CONCLUSION: In high-risk rectal cancer, oxaliplatin-containing neoadjuvant therapy may promote an immune response that
favours survival without metastatic progression.
British Journal of Cancer (2018) 118:1322–1328; https://doi.org/10.1038/s41416-018-0085-y
INTRODUCTION
In locally advanced rectal cancer (LARC), locoregional neoadjuvant
chemoradiotherapy (CRT) with a ﬂuoropyrimidine in a non-
cytotoxic radiosensitising dose and resection of the residual
tumour results in low local recurrence rates.1 However, metastatic
progression remains a dominant cause of failure, as reported by
30–40% of cases in recent trials.2,3 Currently, no consensus exists
to whether postoperative systemic therapy may reduce the
metastatic risk in rectal cancer after neoadjuvant treatment.2,4,5
Alternative strategies involving neoadjuvant chemotherapy
(NACT) prior to or immediately following the radiation have been
investigated in a number of trials.6–13
In a phase II single-arm LARC study, patients were given
oxaliplatin-/ﬂuorouracil-containing induction NACT and sequential
CRT with concomitant oxaliplatin and capecitabine.14 Acknowl-
edging the concerns arising from protraction of the total
treatment time, theoretically permitting tumour cell repopulation
and selective pressure towards the survival of therapy-resistant
cell clones, only 4 weeks of the induction NACT (two cycles of the
Nordic FLOX regimen15) were given. This induction phase was
found to be highly tolerable14 and alone led to substantial tumour
volume reduction.16 Additionally, in a study population with
a high proportion of T4 disease and lymph node involvement,
5-year progression-free survival (PFS; almost all of PFS events were
metastatic progression) and overall survival (OS) were remarkably
good.14
Recent data from preclinical models17–20 and emerging clinical
evidence21 indicate that tumour-targeting immune responses can
be invoked by oxaliplatin-induced tumour cell death as shed
tumour antigens, when captured and presented by dendritic cells,
cause activation of cytotoxic T lymphocytes. In a similar fashion,
radiation is not simply a cytotoxic agent within the treatment
target volume, but may also exert systemic effects that are
immune-mediated22,23 and eradicate occult or clinically estab-
lished tumour at distant sites (the so-called abscopal effect).24–26
When considering the clinical observations in our LARC study
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along with the possibility of oxaliplatin-induced immunogenic cell
death, it was tempting to speculate that the short-course
induction NACT might have unleashed the immune responses
that would commission beneﬁcial systemic effects in addition to
the local clonogenic cell kill by the sequential CRT.
To investigate this hypothesis, we required a surrogate marker
that would exhibit both the direct cytotoxic effects of chemother-
apy and tumour-directed immunity. Hence, we analysed the
circulating levels of the fms-related tyrosine kinase 3 ligand
(Flt3L), a haematopoietic factor27 that reﬂects recovery from
chemotherapy-induced myelosuppression28,29 and causes activa-
tion of mature dendritic cells.30–32 Speciﬁcally, Flt3L is a potent
growth factor for a rare subset of professional antigen-presenting
cells that stimulates cytotoxic T cells.33 Importantly, Flt3L has been
shown to mediate abscopal effect of radiation in an experimental
model,31 and when administered to patients with metastatic
colorectal cancer, it has led to expansion of the dendritic cell
population both in the tumour periphery (locally) and the
peripheral blood (systemically).34
In brief, we observed that a high serum Flt3L level following the
two induction FLOX cycles was associated with low probability of
a PFS event when oxaliplatin dose scheduling during the sequen-
tial CRT did not compromise the radiation delivery. Hence, an
advantageous long-term outcome associated with maintenance of
high circulating Flt3L during oxaliplatin-based neoadjuvant
treatment in rectal cancer patients commonly prone to metastatic
progression suggests that a beneﬁcial systemic immune response
may have been invoked.
METHODS
Patients
Patients eligible for the principal study, conducted in Oslo, Norway
(NCT00278694), had histologically veriﬁed rectal adenocarcinoma
that was either T4, T3 with mesorectal fascia margin of 3 mm or
less, or a tumour of any T stage with lymph node involvement
within 3 mm of this margin, as assessed by magnetic resonance
imaging.14 With respect to eligibility, the only difference in the
independent study cohort from Copenhagen, Denmark
(NCT00964457), was that a margin of ≥1mm of the mesorectal
fascia excluded patients from participating in the study.35 Other
eligibility criteria, evaluation procedures and follow-up have been
described in detail previously.14,35 Anonymised biobank samples
linked to de-identiﬁed selected patient data were transferred
between institutions in accordance with the current regulations.
Treatment and end points of the Oslo cohort
This study was conducted to evaluate the safety, histologic tumour
response and PFS of intensiﬁed neoadjuvant therapy. Induction
NACT was given as two cycles of the Nordic FLOX regimen
(oxaliplatin 85mg/m2 on day 1 and bolus ﬂuorouracil 500mg/m2
and folinic acid 100mg on days 1 and 2 every second week).15
Sequential CRT consisted of radiation delivered ﬁve days per week
to a total dose of 50 Gy in 25 fractions to the tumour bed and 48
Gy in 23 fractions to the regional lymph nodes, based on two-/
three-dimensional conformal planning models, with concomitant
weekly oxaliplatin 50mg/m2 and capecitabine 825mg/m2 twice
daily on days of radiotherapy. Treatment evaluation was done four
weeks after the completion of preoperative therapy, and radical
excision was planned 4–8 weeks after the evaluation. In
accordance with national guidelines at that time, patients did
not proceed to further therapy. Routine blood tests were done
within the standard patient follow-up. The surrogate end points
were histologic scorings of the resected tumour specimens (ypTN
stage) and tumour regression grade (TRG), as presented pre-
viously.14,36–38 TRG1–2 and TRG3–5 were considered as good and
poor tumour response, respectively. Magnetic resonance volume-
try was undertaken after each sequential therapy, as described
previously.39 Tumour volume changes from the baseline volume
(VBASELINE) to after NACT (ΔVNACT) and further from the volume after
NACT to after CRT (ΔVCRT) were calculated as ΔVNACT= [(VNACT−
VBASELINE)/VBASELINE] × 100 and ΔVCRT= [(VCRT – VNACT)/VNACT] × 100,
respectively. The 73 patients included in this report were enrolled
from the 5 October 2005 to the 3 March 2010. Censoring was done
on the 8 August 2013, and PFS and death events were recorded a
maximum of 5 years following pelvic surgery.
Treatment adjustments in the Oslo cohort
The neoadjuvant schedule was continuously adjusted according
to toxicity, as assessed by the Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0, by reducing the doses of
chemotherapy before radiation, and for myelosuppression grade 3
during CRT in particular, by reducing the dose of oxaliplatin more
than that of capecitabine. Of further note in the context of the
present report, oxaliplatin was reduced from CTCAE grade 2
neuropathy, while equal dose reductions of oxaliplatin and
capecitabine were planned for CTCAE grade 2 myelosuppression
and for CTCAE grade 2 and 3 diarrhoea (Supplementary Table S1).
Formal recording of CTCAE scores was carried out at NACT and
CRT completion.
Treatment and end points of the Copenhagen cohort
Treatment of this cohort was not uniform. Patients were given
NACT as 1–4 cycles (2–8 weeks) of oxaliplatin 85 mg/m2 every
second week and capecitabine 650 mg/m2 twice a day continu-
ously. Eighty-ﬁve percent of patients had radiation delivered
ﬁve days per week to a total dose of 54 Gy in 27 fractions to the
tumour bed and 48.6 Gy in 27 fractions to the regional lymph
nodes, based on intensity-modulated planning models. For the
remaining cases, alternative fractionation schedules or delivery
techniques were used. All but one participant had concomitant
capecitabine 825 mg/m2 twice daily continuously, but only 88%
received weekly oxaliplatin 50 mg/m2 during radiotherapy. Finally,
57% of patients received 1–2 cycles of preoperative chemotherapy
(capecitabine with or without oxaliplatin) following CRT comple-
tion. ypTN stage and TRG were scored in the resected tumour
specimens. Patients had pelvic surgery at a median of 5 (range,
2–19) weeks after CRT completion. PFS and OS status was
censored at a median of 64 (range, 2–67) months after study
enrolment; i.e., at the available time point closest to 5 years after
the pelvic surgery for each patient.
Measurement of serum Flt3L levels
Patients had serum sampled at baseline and following the
completion of NACT (post NACT) and CRT (post CRT). Additionally,
the Oslo study patients had serum collected at treatment
evaluation prior to surgery. The collected samples were stored
at –80 °C until analysis. In samples from the Oslo cohort, serum
Flt3L was analysed with the Human Flt-3 Ligand Quantikine®
ELISA Kit (R&D Systems). For practical reasons, analysis of the
Copenhagen samples was performed with a customised Luminex
Multiplex Assay (R&D Systems). One-to-two dilution and two
technical replicates were done for all samples. In 39 randomly
chosen samples covering all three sampling points from a total of
19 patients of the Copenhagen cohort, strong correlation (r= 0.96;
P < 0.01; by Pearson product correlation) was found between Flt3L
levels measured by the single-parameter and multiplex assays
(Supplementary Fig. S1).
Statistical analysis
Analyses were performed using IBM SPSS Statistics for Mac version
24.0 and GraphPad Prism version 6.0h. Groups were compared
either using unpaired one-way analysis of variance with Bonferro-
ni’s test for multiple comparisons or Student’s t-test, as appro-
priate. Correlations were determined by Pearson product
correlation analysis after transformation of the data to natural
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logarithms. PFS was calculated from the time of study enrolment
to the date of recurrent disease (diagnosis of local recurrence
or distant metastasis), death of any cause, or end of follow-up,
whichever occurred ﬁrst. Associations between the selected
variables and the PFS were modelled with univariate Cox
regression analysis and further analysed by multivariate Cox
regression using backwards stepwise conditional selection, as
appropriate, and the results were expressed as hazard ratio (HR)
with 95% conﬁdence interval (CI). All reported P values were for
two-sided tests with signiﬁcance level set less than 0.05.
RESULTS
Patient characteristics and serum Flt3L levels—Oslo cohort
The 73 patients mainly presented with T3 (60%) or T4 (33%)
disease (Table 1). Median age was 59 years. As seen in Fig. 1, the
median serum Flt3L level increased from 62.9 (range, 14.4–154)
pg/ml (N= 73) at baseline to 137 (range, 21.3–374) pg/ml (N= 60)
post NACT and further to 205 (range, 126–658) pg/ml (N= 58)
post CRT. At evaluation, the median Flt3L had fallen to 93.7
(range, 14.2–214) pg/ml (N= 56). The serum Flt3L measures
(mean ± SD) during the neoadjuvant treatment course, including
that at evaluation 4 weeks after completion of the neoadjuvant
therapy, were signiﬁcantly different from baseline (P < 0.0001; by
unpaired one-way analysis of variance with Bonferroni’s test for
multiple comparisons).
Cytotoxicity over the course of neoadjuvant therapy
As both post NACT and post CRT serum sampling points
immediately followed the completion of the preceding sequential
therapy, we could investigate whether the individual patient’s
serum Flt3L alteration at each of the sampling points (fold-change
from the preceding one) might correlate with myelosuppressive
effects (in terms of fold-change of absolute peripheral blood
Table 1. Description of cohorts
Oslo Copenhagen
N (%) N (%)
Total cohort 73 (100) 65 (100)
Age, years
Median (range) 59 (30–73) 67 (41–78)
Gender
Male 42 (58) 39 (60)
Female 31 (42) 26 (40)
T stage
T2 5 (7) 0
T3 44 (60) 31 (48)
T4 24 (33) 34 (52)
N stage
N0 9 (12) 16 (25)
N1 8 (11) 15 (23)
N2 55 (75) 21 (32)
ND 1 (1.4) 13 (20)
ypT stage
ypT0 15 (21) 7 (11)
ypT1 7 (10) 3 (4.6)
ypT2 17 (23) 9 (14)
ypT3 22 (30) 30 (46)
ypT4 11 (15) 11 (17)
ND 1 (1.4) 5 (7.7)
ypN stage
ypN0 52 (71) 47 (72)
ypN1 16 (22) 10 (15)
ypN2 4 (5) 3 (5)
ND 1 (1.4) 5 (7.7)
TRG score
TRG1–2 53 (73) 23 (35)
TRG3–5 19 (26) 35 (54)
ND 1 (1.4) 7 (11)
ND not determined, TN tumour node, TRG tumour regression grade, yp
histologic response to neoadjuvant therapy
Oslo
Baseline Post NACT Post CRT Evaluation Baseline Post NACT Post CRT
1000 1000
100
10
100
10
FI
t3
L 
(pg
/m
l)
Copenhagen
Fig. 1 Serum Flt3L levels during the neoadjuvant treatment course in the Oslo and Copenhagen patient cohorts. The horizontal line in each
data cluster represents the median value. CRT chemoradiotherapy, Flt3L fms-like tyrosine kinase 3 ligand, NACT neoadjuvant chemotherapy
Table 2. Treatment-induced changes in circulating Flt3L levels and
correlations with cytotoxic effects – Oslo study
Measure of cytotoxicity Post NACT Post CRT
N r P N r P
Haemoglobin 56 –0.38 <0.01 49 0.02 0.87
Thrombocytes 56 –0.07 0.62 49 –0.34 0.02
Neutrophils 56 –0.36 0.01 49 –0.19 0.19
Lymphocytes 54 0.27 0.05 47 0.11 0.46
Monocytes 53 0.07 0.60 40 0.47 0.01
Tumour ΔVa 49 –0.32 0.03 43 0.07 0.67
CRT chemoradiotherapy, Flt3L fms-like tyrosine kinase 3 ligand, NACT
neoadjuvant chemotherapy aΔV denotes ΔVNACT post NACT and ΔVCRT post
CRT
Immune response against rectal cancer metastasis...
E Kalanxhi et al.
1324
measures) and the immediate tumour response (ΔV) to the
respective treatment, as a manifestation of its cytotoxicity
(Table 2). At NACT completion, a signiﬁcant negative correlation
was found between changes in levels of Flt3L and those of
haemoglobin and neutrophils. The corresponding correlation with
thrombocytes at CRT completion reﬂected a more protracted
effect, commonly observed with oxaliplatin-containing regimens.
Interestingly, at this time point there was also a positive
correlation between changes in the levels of Flt3L and monocytes.
Of further note, the immediate treatment response in terms
of relative tumour volume shrinkage (negative ΔV value) was
correlated with an increase in the Flt3L level only after induction
NACT. In this regard, the histologic tumour response to radiation
in rectal cancer is not manifest until 6–8 weeks following
administration of the total dose.40
Serum Flt3L levels and treatment outcome
In further support of a potential connection between myelosup-
pressive effects and beneﬁcial treatment response, absolute serum
Flt3L levels at baseline and post NACT were found to be
signiﬁcantly higher in patients with good histologic tumour
response (TRG1–2), as compared to those with poor response
(TRG3–5) following the neoadjuvant therapy; however, no differ-
ence was seen with regard to histologic ypTN stage (Supplementary
Table S2). When censored, the median follow-up time was 65 (range,
3–66) months. The majority of PFS events consisted of metastatic
progression, all of which occurred after completion of the
neoadjuvant therapy. The 5-year PFS was 68%. As shown in Table 3,
post NACT serum Flt3L level was strongly associated with the
outcome; the higher circulating Flt3L level following the short-
course FLOX therapy, the better PFS (HR: 0.15; 95% CI: 0.04–0.55;
P < 0.01 for a PFS event with high Flt3L level; by multivariate Cox
regression analysis). This feature applied speciﬁcally to T4 cases
(Supplementary Table S3). Pertaining to the entire Oslo cohort,
post NACT Flt3L level was statistically stronger as a prognostic
marker than baseline T stage, but not signiﬁcant when compared
to postoperative ypT stage (Supplementary Table S4); histologic
tumour response is regarded as a superior determinant of
recurrence risk after neoadjuvant CRT.1 Moreover, a long interval
between disease progression and death was reﬂected by a 5-year
OS of 88%. Correspondingly, for cases with recorded PFS events or
death at censoring, median time to progression was 14 (range,
3–52) months, but 31 (range, 8–66) months for death.
Adjustment of oxaliplatin dose and PFS
As shown in Table 4, the induction NACT was well tolerated and
90% of patients received the intended dose. However, the
majority of patients experienced chemotherapy dose reduction
during the sequential CRT, consistent with dose adjustments of
both chemotherapeutics planned already at CTCAE grade 2
myelosuppression or diarrhoea (Supplementary Table S1). Only
19% of patients received the full-prescribed chemotherapy doses
over the entire neoadjuvant treatment; while 67% had reduction
in capecitabine during CRT, 77% did not receive the full-oxaliplatin
dose (Table 4). Per protocol, cases with grade 3 neutropenia would
have oxaliplatin dose lowered more than capecitabine dose, and
cases with grade ≥2 neuropathy would have oxaliplatin admin-
istration interrupted or discontinued (Supplementary Table S1).
Over the active neoadjuvant treatment, a total of 42 CTCAE grade
2–3 events of neutropenia, diarrhoea, paraesthesia, or hand-foot
syndrome were reported (Supplementary Table S5). During CRT
(Table 4), 29 patients (40% of the 73 study participants) had
reduction in oxaliplatin dose because of neutropenia, diarrhoea
and paraesthesia (32 events in total; Supplementary Table S5),
leaving 27 patients (37% of participants) with oxaliplatin dose
adjustment of other reasons such as fatigue, fever, vomiting and
anorexia. The details on all recorded CTCAE grade 3–5 adverse
events have been reported previously.14
As further shown in Table 4, reduction in the planned oxaliplatin
dose during CRT was by a narrow margin associated with
advantageous PFS (HR: 0.47; 95% CI: 0.22–0.99; P= 0.046 for a
PFS event in patients with dose reduction; by multivariate Cox
regression analysis). However, this association was lost when the
time to reduction in the neoadjuvant course was included as a
covariate in the analysis (data not shown). This analysis was done
because PFS was calculated from the time of study enrolment and
therefore, dose adjustment at later time points might have led to
bias in the analysis. Moreover, in CRT, capecitabine is used for its
radiosensitising properties at a non-cytotoxic dose,41 and reduced
doses were not associated with PFS (Table 4). With respect to the
radiotherapy, only two of the 73 participants (2.7%) did not
receive the total dose of ≥50 Gy; ﬁve of the seven patients who
had interruption in radiation delivery (owing to CTCAE grade 3
diarrhoea before CRT completion; Supplementary Table S1)
received compensation to ensure biological equivalence in
efﬁcacy.42 Hence, for a majority of patients, the reported side
effects of chemotherapy did not compromise delivery of the full-
prescribed radiation dose.
Serum Flt3L levels—Copenhagen cohort
In this cohort, which met the criterion of comprising LARC patients
given sequential neoadjuvant therapy along with simultaneous
serial serum sampling and available long-term outcome data, 20%
and 80% of patients had received 2–4 weeks or 6–8 weeks,
respectively, of oxaliplatin-based induction NACT. A total of 65
patients were older (median age 67 years) with a higher
Table 3. Circulating Flt3L levels during the treatment course and PFS–
Oslo study
Sampling point N HR (95% CI)a P
Baseline 73 9.5 (1.2–80) 0.04
Post NACT 60 0.15 (0.04–0.55) <0.01
Post CRT 58 1.1 (0.17–7.7) 0.90
Evaluation 56 0.43 (0.15–1.2) 0.11
CI conﬁdence interval, CRT chemoradiotherapy, Flt3L fms-like tyrosine
kinase 3 ligand, HR hazard ratio, NACT neoadjuvant chemotherapy, PFS
progression-free survival aLow HR indicates favourable PFS (low probability
of a PFS event) with high Flt3L level
Table 4. Chemotherapy dose adjustments during the treatment
course and PFS–Oslo study
Therapy Dose N (%) HR (95% CI)a P
Induction NACT Full 66 (90)
Reduced 7 (10) 0.64 (0.15–2.7) 0.54
Sequential CRT—
oxaliplatin
Full 17 (23)
Reduced 56 (77) 0.47 (0.22–0.99) 0.046
Sequential CRT—
capecitabine
Full 24 (33)
Reduced 49 (67) 2.8 (0.75–10) 0.13
Entire neoadjuvant
treatment
Full 14 (19)
Reduced 59 (81) NA NA
CI conﬁdence interval, CRT chemoradiotherapy, HR hazard ratio, NA not
applicable, NACT neoadjuvant chemotherapy, PFS progression-free survival
aLow HR indicates favourable PFS (low probability of a PFS event) with
chemotherapy dose reduction
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percentage of T4 cases (52%), when compared to the Oslo cohort
(Table 1). With regard to serum Flt3L levels, as assessed with
an assay that gave Flt3L measures at higher concentrations
(Supplementary Fig. S1), a similar pattern of changes was
observed during the treatment course (Fig. 1). The median Flt3L
level was 110 (range, 47.0–215) pg/ml (N= 59) at baseline that
increased signiﬁcantly to 188 (range, 58.1–535) pg/ml (N= 58)
post NACT and 228 (range, 111–474) pg/ml (N= 28) post CRT. Of
note, the relative increment in circulating Flt3L from baseline
to NACT completion was higher in the Oslo cohort (P= 0.03 on
comparison). Further on, compared to the Oslo counterparts, the
Copenhagen patients had considerably worse histologic tumour
response (ypT3–4 stage and TRG3–5 score; Table 1), which might
be related to the greater number of T4 cases. Other dissimilarities
of note were the 5-year PFS and OS that were strikingly equal
(71% and 69%, respectively, for the entire cohort), as were also the
median times to progression [22 (range, 9–63) months] and death
[29 (range, 2–65) months] for cases with these events at censoring.
Finally, no association was found between PFS and serum Flt3L
levels at any sampling point (Supplementary Table S3).
DISCUSSION
Circulating levels of the haematopoietic factor Flt3L increased in
two independent cohorts of LARC patients during induction
NACT and further over sequential CRT, both modalities contain-
ing oxaliplatin. In the Oslo cohort, the higher Flt3L level
following the induction NACT, the more favourable 5-year PFS
without metastatic progression. This cohort had available dose
scheduling and toxicity data, which revealed that oxaliplatin
dose reduction during CRT, undertaken to avert breach of
radiation delivery, was associated with the advantageous PFS.
Elevation of the circulating Flt3L level reﬂects recovery from
chemotherapy-induced myelosuppression,28,29 and it expands
the pool of professional antigen-presenting dendritic cells.33
Despite missing validation in the Copenhagen cohort, the
present data support the notion that oxaliplatin-based neoad-
juvant therapy, when administered at an intensity sufﬁcient to
maintain patient compliance to the radiotherapy protocol, may
promote an immune response that enables eradication of occult
microscopic tumour at distant sites (abscopal effect) in LARC
patients prone to develop metastatic disease.
Metastatic progression in spite of local tumour control
represents a major challenge in the treatment of LARC. Hence,
varying combinations of multimodal therapy have been
evaluated with the aim of preventing systemic dissemination.
Chemotherapy consisting of oxaliplatin and a ﬂuoropyrimidine has
been administered before CRT (in trials not randomised for the
induction therapy) or followed short-course radiation prior to
surgery (the experimental arm of the recently concluded RAPIDO
trial; efﬁcacy data are not yet reported) in an attempt to deliver
adequate systemic therapy for metastasis prevention without
compromising local disease control.6–13 Because radiation has the
ability to deliver cytotoxic effects in a focused tumour volume,
it has been argued that improved systemic outcome may be
achieved by intensifying the local effects that enhance elimination
of clonogenic cells.43 In that regard, only two of seven randomised
studies that have evaluated the potentially radiosensitising effect
of concomitant oxaliplatin in ﬂuoropyrimidine-based CRT met the
primary efﬁcacy end point, although in several of the studies
fewer experimental arm patients seemed to have metastatic
disease at surgery.3,44–49 The same two studies showed high
patient compliance to the chosen dose scheduling of oxalipla-
tin;3,45 c.f., Supplementary Table S6. In the present study cohorts,
induction oxaliplatin-based NACT was administered before
long-course CRT where oxaliplatin was given concomitantly
for the majority of patients, with the intention of intensifying
local radiation effects but with minimal protraction of the total
neoadjuvant treatment time and maintenance of compliance. This
approach might have caused repetitive myelosuppression
(because oxaliplatin was dosed at sufﬁcient intensity for the
individual patient), resulting in elevated circulating Flt3L levels as
a rescue response during the neoadjuvant treatment course, and
thereby enhanced the pool of functionally active immune cells
and the mediation of systemic tumour-targeting effects. Several
observations supported this notion.
Firstly, serum Flt3L levels increased as an immediate response
to induction NACT and were higher than baseline even 4 weeks
after completion of the full neoadjuvant therapy. Secondly, the
initial relative increase in Flt3L levels was correlated with the
relative decline in neutrophils, which has also been observed
previously.28 Additionally, at CRT completion, Flt3L induction was
correlated with an increase in the monocyte count, an indirect
measure of the presumed haematopoietic effect on dendritic
cells appearing over the treatment course. Moreover, in the Oslo
cohort, the increase in serum Flt3L levels during the induction
NACT was correlated with tumour volume shrinkage (local
response), and a high absolute Flt3L level at this instance was
associated with a good TRG score (local response) and favourable
5-year PFS (systemic response), where the local response
measures are surrogate end points for the ﬁnal outcome. Of
further note, median OS and 5-year OS were considerably better
than the corresponding PFS measures. Finally, the observed
association between oxaliplatin dose reduction during CRT and
an advantageous long-term outcome supported the notion of
maintenance of a systemic anti-tumour immune response,50
strengthened by the ﬁnding of serum Flt3L elevation during
induction NACT and further during sequential CRT in the
independent Copenhagen cohort.
However, in the Oslo cohort, patients’ post CRT Flt3L level
(signiﬁcantly different from baseline) was not predictive of PFS.
Although the observed association between post NACT Flt3L level
and PFS may be a chance ﬁnding, it would not be entirely
surprising that the timing of the Flt3L increase may be important.
Remaining speculative without further studies, it could still be that
the two cycles of the Nordic FLOX regimen unleashed the
advantageous systemic responses just prior to the administration
of the main therapeutic modality (CRT). In this context, it is
worth noting that the heterogeneous neoadjuvant regimens in
the Copenhagen cohort might have contributed to the lack of
association between PFS and circulating Flt3L.
There are several weaknesses inherent to the present study.
Importantly, this set of analyses was not planned at the time of
trial conduct, but prompted by the evidence that appeared as
we started to look at clinical outcome data. Hence, none of the
performed analyses had been prespeciﬁed in a statistical
analysis plan. Both study cohorts are relatively small, but our
attempts in identifying other independent studies holding all of
the required criteria have been unsuccessful. There were
considerable dissimilarities between the two cohorts. The Oslo
and Copenhagen patients had different distribution of age and
TN stage, and they did not receive exactly the same neoadjuvant
treatment. The former cohort had 4 weeks of oxaliplatin-
containing NACT, however, 80% of the latter cohort had this
treatment for a longer period (6–8 weeks). The relative
increment in the circulating Flt3L during NACT was signiﬁcantly
lower in the latter and not associated with PFS, which might
indicate that oxaliplatin had not been dosed at sufﬁcient
intensity. More than 10% of Copenhagen patients did not
receive concomitant oxaliplatin (to maintain the presumed
optimum Flt3L level for an advantageous long-term outcome),
and the median and 5-year PFS and OS measures were strikingly
similar in this cohort. Despite the emerging data demonstrating
that oxaliplatin is responsible for ‘on-target’ immunogenic cell
death17–21 and ‘off-target’ anti-tumour immune responses,21 this
drug was one component with other cytotoxic therapies in the
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multimodal treatment regimens. It is also important to keep in
mind that the radiotherapy technique used in the Oslo cohort
was based on two-/three-dimensional conformal planning that
might have caused irradiation of pelvic bone marrow, thus
contributing to the observed haematological toxicity. A relevant
dose-volume parameter to assess such contribution has not
been determined. Furthermore, we found that oxaliplatin dose
adjustment as such, and not the grade of severity of
myelosuppression,51 was prognostic for improved survival. The
association was not strong and was lost when the time to dose
adjustment in the neoadjuvant course was included as a
covariate in the analysis. However, the analysis was done for a
preset accumulative dose of chemotherapy in a deﬁnite
neoadjuvant regimen. Hence, the data indicate that oxaliplatin
dose reduction as such, and not the exact time for this event
within the neoadjuvant course, was relevant for patient survival.
Finally, data on prophylactic use of granulocyte colony-
stimulating factor were not recorded within the study.
In conclusion, oxaliplatin-containing neoadjuvant therapy that
causes normal tissue toxicity that is sufﬁcient to maintain a high
level of circulating Flt3L but does not compromise patient
compliance to the radiotherapy, may favour survival without
metastatic progression of LARC patients otherwise prone to
this event. In the era of identifying the optimum context of
immune-modulating therapies, one recommendation might use a
short-course oxaliplatin-based therapy to condition the immune
system and transform LARC, or metastatic colorectal cancer, into
an immunogenic disease before sequential immune checkpoint
blockade, currently in the forefront of combination cancer
therapies.
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